Patents Assigned to The Council of the Queensland Institute of Medical Research
-
Publication number: 20090304660Abstract: The invention relates to a method for inducing immunological tolerance, in particular transplantation tolerance, by administering a G-CSF derivative or biologically active fragment, homolog, or variant thereof, in particular peg-G-CSF, to a donor cell or a transplantation donor. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursor cells and IL-10 secreting T cells.Type: ApplicationFiled: August 20, 2009Publication date: December 10, 2009Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCHInventors: Geoffrey HILL, Kellie MACDONALD, Edward MORRIS
-
Patent number: 7569225Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.Type: GrantFiled: August 12, 2003Date of Patent: August 4, 2009Assignee: The Council of The Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Patent number: 7524503Abstract: The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the most commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine compositions comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject.Type: GrantFiled: June 26, 2002Date of Patent: April 28, 2009Assignee: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Rebecca Ann Elkington, Susan Jennifer Walker
-
Publication number: 20080175868Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: ApplicationFiled: July 24, 2007Publication date: July 24, 2008Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H. Lowell, George L. White, Michael Raymond Batzloff, David S. Burt, Tomas B. Leanderson, Michael F. Good
-
Patent number: 7341997Abstract: The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.Type: GrantFiled: April 7, 2005Date of Patent: March 11, 2008Assignees: The Walter and Eliza Hall Institute of Medical Research, The Council of the Queensland Institute of Medical Research, The University of MelbourneInventors: Perry F. Bartlett, Lynne Hartley, Mark Pouzzotto, Trevor Kilpatrick, Frank Kontgen, Jason Coonan, Ursula Greferath, Andrew W. Boyd, Mirella Dottori, Mary P. Galea, George Paxinos, Mark Murphy
-
Patent number: 7288398Abstract: The present invention related generally to novel molecules and more particularly novel proteinaceous molecules involved in or associated with regulation of cell activities and/or viability. The present invention is particularly directed to novel serine proteinases and a novel kinase and to derivatives, agonists and antagonists thereof. In one embodiment, the present invention provides a novel serine proteinase, referred to herein as “HELA2” or “testisin”, which has roles in spermatogenesis, in suppressing testicular cancer and as a marker for cancers.Type: GrantFiled: January 7, 2002Date of Patent: October 30, 2007Assignee: The Council of the Queensland Institute of Medical ResearchInventors: Toni Marie Antalis, John David Hooper
-
Patent number: 7255867Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: GrantFiled: November 13, 2003Date of Patent: August 14, 2007Assignees: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George H Lowell, George L White, Michael R Batzloff, David S Burt, Tomas B Leanderson, Michael F Good
-
Publication number: 20070041937Abstract: The invention relates to a method, composition and use thereof for inducing immunological tolerance, in particular transplantation tolerance in a recipient and self-tolerance in a patient. Tolerance is preferably induced by administering a G-CSF derivative, or biologically active fragment, homolog or variant thereof, in particular peg-G-CSF, to a transplantation donor. Transplantation tolerance may reduce or prevent graft versus host disease or graft rejection and self-tolerance may prevent, treat or improve a condition in relation to an autoimmune disorder. The invention also relates to expanding and stimulating selected donor cells by administering a G-CSF derivative, preferably peg-G-CSF. The donor cells are preferably granulocyte-monocyte precursors cells and IL-10 secreting T cells.Type: ApplicationFiled: August 20, 2004Publication date: February 22, 2007Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCHInventors: Geoffrey Hill, Kellie MacDonald, Edward Morris
-
Publication number: 20060204514Abstract: Methods are disclosed for the design of non-native (i.e. heterologous) polypeptides comprising a proportion of hydrophobic amino acids which have an increased probability of being efficiently expressed in an expression system such as a bacterial host (e.g. E. coli). The methods involve identifying one or more hydrophobic peptide sequences within a polypeptide of interest, and arranging or re-locating at least one of the hydrophobic peptide sequences within said polypeptide so as to generate a candidate polypeptide with reduced amplitude in hydrophobicity and/or length of any hydrophobic region(s). Such methods are particularly useful for designing polyepitope polypeptides, and specific examples of such are described for Epstein-Barr virus (EBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).Type: ApplicationFiled: July 14, 2003Publication date: September 14, 2006Applicants: CSL Limited, The Council of the Queensland Institute of Medical ResearchInventors: Elizabeth Webb, Peter Schoofs
-
Publication number: 20060199177Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of EPINQALTLMTKNVKPL (SEQ ID NO: 12); FAGVVLAGVALGVATAA (SEQ ID NO: 13); NLNAQAIQSLRTSLEQS (SEQ ID NO: 17) and TELLSIFGPSLRDPISA (SEQ ID NO: 20).Type: ApplicationFiled: May 4, 2006Publication date: September 7, 2006Applicants: CSL Limited, The University of Melbourne, Commonwealth Scientific and Industrial Research Organisation, The Council of Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical ResearchInventors: David Jackson, Souravi Ghosh, John Walker
-
Patent number: 7097844Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of PRTSDRPVSYTMNRTRS (SEQ ID NO: 4); TRSRKQTSHRLKNIPVH (SEQ ID NO: 5); SHQYLVIKLIPNASLIE (SEQ ID NO: 6); and SPDKLLTFIASDTCPLV (SEQ ID NO: 25).Type: GrantFiled: November 13, 2003Date of Patent: August 29, 2006Assignees: CSL Limited, The University of Melbourne, Commonwealth Scientific and Industrial Research Organisation, The Council of Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical ResearchInventors: David Charles Jackson, Souravi Ghosh, John Walker
-
Publication number: 20050186220Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of PRTSDRPVSYTMNRTRS (SEQ ID NO: 4); TRSRKQTSHRLKNIPVH (SEQ ID NO: 5); SHQYLVIKLIPNASLIE (SEQ ID NO: 6); and SPDKLLTFIASDTCPLV (SEQ ID NO: 25).Type: ApplicationFiled: November 13, 2003Publication date: August 25, 2005Applicants: The University of Melbourne, CSL Limited, Commonwealth Scientific and Industrial Research Organization, The Council of the Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical ResearchInventors: David Jackson, Souravi Ghosh, John Walker
-
Publication number: 20050181981Abstract: The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.Type: ApplicationFiled: April 7, 2005Publication date: August 18, 2005Applicants: The Walter and Eliza Hall Institute of Medical Research, The Council of the Queensland Institute of Medical Research, The University of MelbourneInventors: Perry Bartlett, Lynne Hartley, Mark Pouzzotto, Trevor Kilpatrick, Frank Kontgen, Jason Coonan, Ursula Greferath, Andrew Boyd, Mirella Dottori, Mary Galea, George Paxinos, Mark Murphy
-
Publication number: 20050037014Abstract: The present invention provides T helper cell epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes. The epitopes are contained within a peptide sequence selected from the group consisting of SSKTQTHTQQDRPPQPS (SEQ ID NO: 1); QPSTELEETRTSRARHS (SEQ ID NO: 2); QSLRTSLEQSNKAIEEI (SEQ ID NO: 18); and DESSCVFVSESAICSQN (SEQ ID NO: 23).Type: ApplicationFiled: September 8, 2004Publication date: February 17, 2005Applicants: The University of Melbourne, CSL Limited, Commonwealth Scientific and Industrial Research Organisation, The Council of the Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical ResearchInventors: David Jackson, Souravi Ghosh, John Walker
-
Publication number: 20050002956Abstract: Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.Type: ApplicationFiled: November 13, 2003Publication date: January 6, 2005Applicants: ID Biomedical Corporation of Quebec, The Council of the Queensland Institute of Medical ResearchInventors: George Lowell, Gregory White, Michael Batzloff, David Burt, Tomas Leanderson, Michael Good
-
Patent number: 6723695Abstract: The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.Type: GrantFiled: May 30, 2000Date of Patent: April 20, 2004Assignees: Council of the Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation of Limestone Avenue, The University of Melbourne of Royal Parade, Walter and Elisa Hall Institute of Medical Research of Royal Melbourne Hospital, CSL LimitedInventors: Scott Renton Burrows, Rajiv Khanna, Martina Alison Sherritt
-
Patent number: 6703024Abstract: The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQVAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPTG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.Type: GrantFiled: August 1, 2001Date of Patent: March 9, 2004Assignees: The Council of the Queensland Institute of Medical Research, CSL Limited, Biotech Australia PTY Limited, The Walter & Eliza Hall Institute of Medical Research, The University of Melbourne, Commonwealth Scientific and Industrial Research OrganisationInventors: Rajiv Khanna, Beverley Mavis Kerr, Ihor Stephan Misko, Denis James Mòss, Scott Renton Burrows
-
Patent number: 6699477Abstract: The present invention provides an isolated cytotoxic Epstein-Barr virus T-cell epitope having the amino acid sequence TYSAGIVQI (SEQ ID NO: 34) which can be formulated as a water-in-oil formulation, and vaccine compositions comprising said epitope, optionally with additional epitopes.Type: GrantFiled: August 1, 2001Date of Patent: March 2, 2004Assignees: The Council of the Queensland Institute of Medical Research, CSL Limited, Biotech Australia PTY Limited, The Walter & Eliza Hall Institute of Medical Research, The University of Melbourne, Commonwealth Scientific and Industrial Research OrganisationInventors: Rajiv Khanna, Beverley Mavis Kerr, Ihor Stephan Misko, Denis James Moss, Scott Renton Burrows
-
Patent number: 6685947Abstract: The present invention provides T helper cells epitopes and compositions for use in inducing an immune response comprising at least one of these epitopes.Type: GrantFiled: March 22, 2002Date of Patent: February 3, 2004Assignees: CSL Limited, The University of Melbourne, Commonwealth Scientific and Industrial Research Organisation, The Council of Queensland Institute of Medical Research, Walter and Eliza Hall Institute of Medical ResearchInventors: David Charles Jackson, Souravi Ghosh, John Walker
-
Publication number: 20030175300Abstract: The present invention provides cytotoxic Epstein-Barr virus T-cell epitopes. These epitopes are QVKWRMTTL, VFSDGRVAC, VPAPAGPIV, TYSAGIVQI, LLDFVRFMGV, QNGALAINTF, VSSDGRVAC, VSSEGRVAC, VSSDGRVPC, VSSDGLVAC, VSSDGQVAC, VSSDGRVVC, VPAPPVGPIV, VEITPYEPTG, VEITPYEPTW, VELTPYKPTW, RRIYDLIKL, RKIYDLIEL and PYLFWLAGI. The present invention further provides vaccines including one or more of these epitopes, optionally with additional epitopes.Type: ApplicationFiled: August 1, 2001Publication date: September 18, 2003Applicant: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Beverely Mavis Kerr, Ihor Stephen Misko, Denis James Moss, Scott Renton Burrows